401 research outputs found
Fármacos biotecnológicos y quimioterapia antiinfecciosa
Developments in biotechnology in recent years have enabled the discovery of new pharmacological agents for the treatment and prophylaxis
of infectious diseases. The agents obtained from these biotechnological procedures possess specific characteristics which significantly distinguish
them from drugs obtained by chemical synthesis. These properties cover the entire development process, from investigation and production
up to their administration to patients. The pharmokinetics of these preparations influence their administration routes and dosage regimens.
The discovery of these drugs has led to major advances in the treatment and prophylaxis of infectious processes which until very recently
had no effective treatment. The investigation and production of these drugs requires the use of highly technical resources resulting in
high costs and therefore a more expensive drug on the market compared to other drugs. Nevertheless, well documented pharmoeconomic
studies show that the use of this type of drug for certain symptoms may be highly cost effective. This article includes some of the possible applications
of biotechnology in the infectious disease field, although the current situation indicates that more detailed and broader applications
may be elaborated on in ensuing issues. The future of these drugs in chemical therapy for the treatment and prophylaxis of infectious diseases
is exceedingly promising and many of these drugs are currently under laboratory investigation, more so than those under development
from a chemical synthesis approach
Production of doubly charged vector bilepton pairs at colliders
The production of pairs of doubly charged vector bileptons is studied at
future colliders. The unpolarized cross--section for the
subprocess is analytically calculated and
convoluted to predict the number of events in the complete process. The gauge or non--gauge character of the
vector bilepton is discussed. It is found that as a consequence
of its spectacular signature, as it decays dominantly into two identical
charged leptons, and also due to its charge contents, which significantly
enhance the cross--section, the detection of this class of particles with mass
in the sub--TeV region can be at the reach of these colliders. The
model--independent nature of our results is stressed.Comment: 9 pages, 7 figures, submitted to physical review
Light charged Higgs boson production at the Large Hadron electron Collider
We study the production of a light charged Higgs boson at the future Large
Hadron electron Collider (LHeC), through the process
considering both decay channels and in the final state. We analyse these processes in the context of the
2-Higgs Doublet Model Type III (2HDM-III) and assess the LHeC sensitivity to
such signals against a variety of both reducible and irreducible
backgrounds. We confirm that prospects for detection in the 2HDM-III are
excellent assuming standard collider energy and luminosity conditions.Comment: 12 pages, 12 figures. Accepted in Physical Review
Review: mitochondrial defects in breast cancer
Mitochondria play important roles in cellular energy metabolism, free radical
generation, and apoptosis. Mitochondrial DNA has been proposed to be involved in
carcinogenesis because of its high susceptibility to mutations and limited repair
mechanisms in comparison to nuclear DNA. Breast cancer is the most frequent
cancer type among women in the world and, although exhaustive research has been
done on nuclear DNA changes, several studies describe a variety of mitochondrial
DNA alterations present in breast cancer. In this review article, we to provide a
summary of the mitochondrial genomic alterations reported in breast cancer and
their functional consequences
- …